In addition, the use of blood-based biomarkers may offer the possibility to test a wide range of other candidate pathophysiological biomarkers, reflecting the full spectrum of disease and driving molecular mechanisms underlying AD, beyond the standard amyloid- and tau-based tests21. Here, MAPT is linked to Alzheimer disease.